When the Insider debuted in February of 2000, the introductory editorial explained that it was dedicated to “digging beneath the hype, the spin, and the underlying data to analyze the promise of HIV/AIDS research—or lack thereof.” We could not have put the hype and spin in perspective without the expert insight of our medical reviewers, who generously extended themselves, often under tight deadlines. We are particularly indebted to Drs. Howard Grossman and Keith Henry for their years of helpful feedback. Our translators were also committed to providing our information to a non-English speaking public, and we thank them for the services they provided, sometimes at reduced rates. Lastly, we thank HIV Plus and Impacto! These publications were the vehicles for the print editions of the newsletter.

Big Leaks in the Bristol Pipeline
Atazanavir’s Debut
HIV Erupts in Russia

July 2003 (Vol. 4, No. 4)

Psoriasis and HIV Keystone Vaccine Symposium International Businesses Confront AIDS

May 2003 (Vol. 4, No. 3)

The Price of Resistance Treatment Interruptions Retain Their Appeal Vaccine Research at a Crossroad AIDSVAX: Maybe It Only Works in Chicago Tenofovir as Pre-Exposure Prophylaxis

April 2003 (Vol. 4, No. 2)

Modest Advances in Hep C Treatment Come at a Hefty Price Female Barrier Contraceptive Finds New Role in HIV Cuba Fights AIDS its own Way

February 2003 (Vol. 4, No. 1)

Glasgow Conference Adds to Treatment Controversies Morocco’s Bold Experiment: Treatment as Prevention

December 2002 (Vol. 3, No. 6)

Tenofovir's a Hit — on the Street and at the Bank RNA Interference: Teaching Cells New Antiviral Tricks Mexico’s Rural HIV Fighters Forced to Improvise a midst Official Neglect

Terrorism & HIV
Preventing Mother-to-Child-Transmission in Uganda
Tenofovir Approved by the FDA
Western Cape's MTCT Program